{"id":"novavax-recombinant-protein-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Myalgia"},{"rate":"25-35","effect":"Headache"},{"rate":"10-15","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Novavax vaccines use recombinant protein technology to produce viral antigens (such as spike proteins) that are combined with an adjuvant to enhance immunogenicity. These antigens are presented to the immune system to generate both antibody and T-cell mediated immune responses, providing protection against infection without using live virus or genetic material integration.","oneSentence":"A recombinant protein vaccine that presents viral antigens to stimulate adaptive immune responses against infectious pathogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:49.797Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (marketed as Nuvaxovid)"},{"name":"Respiratory syncytial virus (RSV) prevention (pipeline)"}]},"trialDetails":[{"nctId":"NCT07051031","phase":"PHASE4","title":"COVID-19 Reactogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcel Curlin","startDate":"2025-10-01","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT07287137","phase":"PHASE4","title":"Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-11-12","conditions":"COVID -19, COVID - 19, COVID 19","enrollment":54},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Novavax recombinant protein vaccine","genericName":"Novavax recombinant protein vaccine","companyName":"Henry M. Jackson Foundation for the Advancement of Military Medicine","companyId":"henry-m-jackson-foundation-for-the-advancement-of-military-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A recombinant protein vaccine that presents viral antigens to stimulate adaptive immune responses against infectious pathogens. Used for COVID-19 prevention (marketed as Nuvaxovid), Respiratory syncytial virus (RSV) prevention (pipeline).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}